| Identification | Back Directory | [Name]
plantamajoside | [CAS]
104777-68-6 | [Synonyms]
Y0160
C10485
dihoside A
Plantamoside
plantamajoside
Purpureaside A
Plantamajoside, 98%, from Plantago major L.
(E)-6-(3,4-Dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-((3,4,5-trihydroxy-6-(hydroxymet
2-(3,4-Dihydroxyphenyl)ethyl 4-O-(3,4-dihydroxycinnamoyl)-3-O-(β-D-glucopyranosyl)-β-D-glucopyranoside
b-D-Glucopyranoside,2-(3,4-dihydroxyphenyl)ethyl 3-O-b-D-glucopyranosyl-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]
β-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 3-O-β-D-glucopyranosyl-, 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]
2-(3,4-Dihydroxyphenyl)ethyl 3-O-beta-D-glucopyranosyl-beta-D-glucopyranoside 4-[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoate]
(2R,3R,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-5-hydroxy-2-(hydroxymethyl)-4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-3-yl (E)-3-(3,4-dihydroxyphenyl)acrylate | [Molecular Formula]
C29H36O16 | [MDL Number]
MFCD20527298 | [MOL File]
104777-68-6.mol | [Molecular Weight]
640.59 |
| Chemical Properties | Back Directory | [Boiling point ]
953.0±65.0 °C(Predicted) | [density ]
1.66 | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Soluble in methanol and water | [form ]
powder | [pka]
9.31±0.10(Predicted) | [color ]
White |
| Hazard Information | Back Directory | [Uses]
food and beverages | [Definition]
ChEBI: Plantamajoside is a hydroxycinnamic acid. | [in vivo]
Plantamajoside (20-80 mg/kg) promotes the recovery of neurological function and protects the tissue structure of the spinal cord after ASCI in a rat model of acute spinal cord injury[15].
Plantamajoside (25-100 mg/kg, i.p., 24 h) alleviates acute sepsis-induced organ dysfunction through inhibiting the TRAF6/NF-κB axis in mice[16].
Plantamajoside (10-40 mg/kg, p.o., 4 weeks) has protective activities against Cd-induced renal injury in rats[17].
Plantamajoside (25-100 mg/kg, i.p., three times at 6, 12, 18 h) ameliorates lipopolysaccharide-induced acute lung injury via suppressing NF-κB and MAPK activation in mice[18].
Plantamajoside (20-80 mg/kg, i.p., once a day for 4 weeks) modulates immune dysregulation and hepatic lipid metabolism in rats with nonalcoholic fatty liver disease via AMPK/Nrf2 elevation[19].
| Animal Model: | Acute sepsis C57BL/6 male mice model by caecal ligation and perforation (CLP)[16] | | Dosage: | 25, 50, 100 mg/kg | | Administration: | Intraperitoneal injection (i.p.), 24 h | | Result: | Extended survival in CLP model.
Improved acute sepsis-triggered organ damage.
Alleviated acute sepsis-triggered apoptosis.
Relieved acute sepsis-triggered inflammatory response.
Improved acute sepsis-triggered organ damage via mediating the TRAF6/NF-κB pathway.
Improved acute sepsis-triggered apoptosis and inflammation via regulating the TRAF6/NF-κB pathway.
|
|
|
|